Evidence map›Paper›PMID 31365276›Full record

ReviewExpert review of hematology2019

Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Akira Satou, N Nora Bennani, Andrew L Feldman

Abstract readReview
In one paragraph

Review in Expert review of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Akira SatouDepartment of Laboratory Medicine and Pathology, Mayo Clinic , Rochester , MN , USA.
N Nora BennaniDivision of Hematology, Mayo Clinic , Rochester , MN , USA.
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic , Rochester , MN , USA.

Funding

Genetic Biomarkers for Risk Assessment of Peripheral T-Cell LymphomasR01CA177734 · NCI · MAYO CLINIC ROCHESTER · PI FELDMAN, ANDREW LEWIS · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA177734
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorBurkitt LymphomaDendritic CellsEpstein-Barr Virus InfectionsHematologic NeoplasmsHistiocytic Disorders, MalignantHodgkin DiseaseHumansKiller Cells, NaturalLymphoma, T-CellMacrophagesNeoplasm ProteinsTerminology as TopicT-LymphocytesWorld Health OrganizationBiomarkers, TumorNeoplasm ProteinsAdult T-cell leukemia/lymphomaEBV-associated T-/NK-cell neoplasmsgenetic abnormalitieshistiocytic/dendritic cell tumorsHodgkin lymphomamature T-cell neoplasmsWHO classification

Identifiers

PMID31365276
PMCPMC6763378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.